Physician profile
Ruby Kwak
NPI 1124606512
$2,447.35
in general payments reported to CMS, 2019-2025
15 companies · $516 in 2025
The $516 reported for 2025 was more than what 79% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $631 · 2023: $764 · 2024: $537 · 2025: $516.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,817.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,816.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $420.95 | 2022-2023 | Winlevi, Ilumya, Absorica Ld |
| Abbvie INC. | $343.67 | 2022-2025 | |
| Genzyme Corporation | $314.96 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $292.87 | 2023-2024 | Sotyktu |
| Dermavant Sciences, INC. | $224.13 | 2024 | Vtama |
| Janssen Scientific Affairs, LLC | $184.23 | 2025 | Tremfya |
| Galderma Laboratories, L.P. | $169.64 | 2022-2023 | Aklief, Oracea, Epsolay |
| Janssen Biotech, INC. | $145.61 | 2024-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $111.43 | 2022-2023 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.38 | 2022-2023 | Spevigo |
| Novartis Pharmaceuticals Corporation | $50.51 | 2024 | |
| Helsinn Therapeutics (U.S.), INC. | $46.91 | 2023 | Valchlor |
| Arcutis Biotherapeutics, INC. | $31.52 | 2025 | Zoryve |
| Ucb, INC. | $27.85 | 2023 | Cimzia |
| Chiesi USA, INC. | $18.69 | 2025 | Filsuvez |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruby Kwak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.